Amorphous complex formed by methotrexate and celecoxib and its application

By preparing amorphous complex of methotrexate and celecoxib under a nitrogen atmosphere and using it for gel patches, the problems of drug insoluble and inhomogeneity are solved, and efficient drug absorption and Stability significantly improves the medication compliance and transdermal effect of rheumatoid arthritis treatment.

CN118542874BActive Publication Date: 2024-12-03LINDMIK PHARM (SUZHOU) CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410502789.4
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-04-25
Publication Date
2024-12-03
Estimated Expiration
2044-04-25

AI Technical Summary

Technical Problem

The existing technology is difficult to effectively solve the problems of insoluble and unevenness of methotrexate and celecoxib, resulting in poor absorption and stability, making it difficult to develop safe and efficient non-oral compound preparations, especially when treating rheumatoid arthritis. Adherence and formulation uniformity challenges.

Method used

Amorphous complex was prepared by mixing methotrexate and celecoxib in dimethyl sulfoxide dissolving and reacting under a nitrogen atmosphere and using it in a gel patch to combine with specific proportions and process conditions, a stable amorphous complex is formed to improve the solubility and uniformity of the drug.

Benefits of technology

The texture uniformity and stability of methotrexate and celecoxib were achieved, the uniformity and drug loading of the preparation were improved, the drug release behavior was extended, the transdermal effect was significantly improved, and maintained at room temperature. After March stability, the drug's trait changes were avoided.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118542874B_ABST
    Figure CN118542874B_ABST
Patent Text Reader

Abstract

The invention discloses an amorphous complex formed by methotrexate and celecoxib and its application, and relates to the technical field of preparation of rheumatoid arthritis-related drugs. The preparation process of the amorphous complex is as follows: methotrexate and celecoxib are mixed, dimethyl sulfoxide is added thereto to dissolve, and the mixture is reacted in a nitrogen atmosphere to prepare the amorphous complex. The invention creatively mixes methotrexate and celecoxib to prepare an amorphous complex, and prepares the amorphous complex into a gel patch. It is found that the amorphous complex has a high release rate of the drug, can significantly improve the release rate, and improve the treatment efficiency.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of preparation of rheumatoid arthritis-related drugs, and more specifically to an amorphous complex of methotrexate and celecoxib and application of the amorphous complex in preparing a patch for treating rheumatoid arthritis. Background Art

[0002] Rheumatoid arthritis (RA) is a systemic disease characterized by synovitis of the joints, accompanied by symptoms such as joint bone damage, dysfunction, and pain, which can lead to joint stiffness, deformity, and even loss of function. If RA patients do not receive timely and effective treatment, they may also develop complications such as Sjögren's syndrome, pericarditis, and anemia. The key to treatment is to control the disease and improve joint function.

[0003] Methotrexate is a dihydrofolate reductase inhibitor that blocks the conversion of exogenous folic acid into tetrahydrofolate, which is an important coenzyme for the synthesis of purine nucleotides and pyrimidine deoxynucleotides in the body. Methotrexate blocks the synthetic metabolic pathway of purine and purine nucleotides and selectively acts on the DNA synthesis phase. Recently, some people believe that this product has a second point of action, namely the G1 / S transition phase. It can also inhibit the synthesis of interleukin-2 and the chemotaxis of neutrophils, thereby playing an anti-inflammatory and anti-proliferative role. Studies have shown that sulfonamides can increase the blood concentration of methotrexate.

[0004] Celecoxib is a nonsteroidal anti-inflammatory drug (NSAID) that selectively inhibits cyclooxygenase 2 (COX-2) and the synthesis of prostaglandins, thereby achieving analgesic, anti-inflammatory and antipyretic effects. Celecoxib has the characteristics of rapid absorption, high oral bioavailability and preferential distribution in inflammatory tissues. Compared with non-selective COX inhibitors, celecoxib has the same analgesic effect, and its gastrointestinal adverse reactions are smaller. However, due to its special crystal structure, it is almost insoluble in water and belongs to poorly soluble drugs.

[0005] Both drugs are oral administration, and oral administration has certain limitations, such as inevitable first-pass effect, adverse effects on the digestive system, and short drug action time, and the need for repeated administration. Especially methotrexate, its mechanism of action has certain cytotoxicity, and the pharmacokinetic characteristics of oral administration can deepen this impact to a certain extent. Moreover, methotrexate and celecoxib are both poorly soluble drugs, and the characteristics of both being difficult to dissolve and difficult to disperse affect the absorption of drugs on the one hand, and on the other hand, the uniformity and stability of the preparation are a huge challenge. During clinical treatment, celecoxib and methotrexate are usually taken in sequence, and the treatment method shows certain clinical advantages, but the method of use still has room for improvement. If both can be prepared into compound preparations, medication compliance can be greatly improved, but there are large differences in the usage and dosage of the two drugs, and there are both poor solubility problems, and the conventional preparation development difficulty is higher. Therefore, it is an urgent need for those skilled in the art to develop a non-oral compound preparation that can be safely and efficiently, uniformly and continuously administered.

[0006] Studies have pointed out that amorphous is a special crystal state, and its physical and chemical properties may be quite different from those of general crystals. Amorphous is also the most favorable form of drug in metastable state to improve drug efficacy. It is generally believed that many substances that can form crystals exist in amorphous state, and their reaction activity is generally greater than that of crystals of the same substance. However, the preparation of amorphous substances and how to maintain the stability of amorphous substances need to be explored in depth. For compounds with different physical and chemical properties, it is necessary to develop targeted preparation methods and find a suitable scope of use.

[0007] Gel patch, belongs to transdermal drug delivery system, is to use water-soluble polymer material as main matrix loaded drug, is coated on the external preparation made on non-woven fabric.Some water-insoluble drugs can be loaded in gel patch by microemulsion system (o / w), and it has the advantages such as small microemulsion particle size, uniform dispersion, good permeability.In addition, gel patch has good skin compatibility, moisturizing and breathable, and weak irritation.However, not all drugs can be loaded with drugs by conventional preparation technology, and exploring new technology or improving and combining existing technology is a major problem that practitioners and technicians need to overcome.

[0008] Therefore, how to prepare methotrexate and celecoxib into an amorphous complex and use the gel patch as a carrier for treating rheumatoid arthritis is a problem that needs to be solved urgently by those skilled in the art. Summary of the invention

[0009] In view of this, the present invention provides an amorphous complex of methotrexate and celecoxib and its application.

[0010] In order to achieve the above object, the present invention adopts the following technical solution:

[0011] The amorphous complex formed by methotrexate and celecoxib is prepared as follows: methotrexate and celecoxib are mixed, dimethyl sulfoxide is added thereto to dissolve, and the mixture is reacted in a nitrogen atmosphere to prepare the amorphous complex.

[0012] Preferably, the molar ratio of methotrexate to celecoxib is 1:15 to 1:20.

[0013] Preferably, the amount of dimethyl sulfoxide added is 1 / 10 of the mass of the mixture of methotrexate and celecoxib.

[0014] Preferably, the reaction in a nitrogen atmosphere is as follows: heat in an oil bath to 160-180° C., stir at 200-400 rpm for 1-2 h, then lower the temperature to 120-140° C., stir at 100 rpm for 30 min, stop stirring and place at this temperature for 24 h, and cool to room temperature to obtain a shiny yellow to orange solid.

[0015] As an inventive concept identical to the above technical solution, the present invention also seeks to protect the use of the amorphous complex in the preparation of a patch for treating rheumatoid arthritis.

[0016] Preferably, the patch is a gel patch.

[0017] As an inventive concept identical to the above-mentioned technical scheme, the present invention also requests protection for a gel patch, comprising the following raw materials in parts by weight: 50 parts of an amorphous complex, 5-10 parts of an emulsifier, 5-10 parts of an emulsifier aid, 50-80 parts of a skeleton material, 60-80 parts of a thickener, 10-15 parts of a stabilizer, 2-5 parts of a whitening agent, 1-3 parts of a cross-linking agent, 10-15 parts of a regulator, 200-300 parts of a moisturizer, and 350-450 parts of water.

[0018] Preferably, the emulsifier is Tween 60 or Tween 80, the co-emulsifier is Span 80 or Span 83, the skeleton material is polyacrylic acid and sodium polyacrylate, the viscosity enhancer is carboxymethyl cellulose or sodium carboxymethyl cellulose, the stabilizer is polyvinyl alcohol, the whitening agent is titanium dioxide, the cross-linking agent is aluminum glycolate or aluminum hydroxide, the regulator is tartaric acid, sodium tartrate or disodium edetate, and the humectant is glycerol or propylene glycol.

[0019] As an inventive concept identical to the above technical solution, the present invention also seeks protection for a method for preparing a gel patch, the process comprising:

[0020] 1) Weigh the compound, emulsifier and co-emulsifier in the formula and disperse them into the moisturizer, stirring at 100 rpm to 300 rpm until the mixture is evenly dispersed;

[0021] 2) Weigh the formulated amount of stabilizer and regulator, disperse them in water, and stir at 50-150 rpm until completely dissolved;

[0022] 3) weighing the skeleton material, tackifier and whitening agent in the formula amount and putting them into the reaction kettle, stirring at 400-600 rpm for 10-30 min, adding the moisturizer while stirring until a uniform paste is formed, then adding the dispersion obtained in step 1), stirring at 100-300 rpm for 10-30 min, and finally adding the crosslinking agent and the solution obtained in step 2), stirring at 100-300 rpm for 10-30 min to form a uniform paste;

[0023] 4) Apply the paste evenly between the backing layer and the protective layer, cut into appropriate size and shape as needed, put into appropriate packaging, and leave for 14 days to obtain the gel patch.

[0024] It can be known through the above-mentioned technical scheme, compared with the prior art, the invention discloses a kind of preparation method comprising methotrexate and celecoxib amorphous complex and its application on gel patch, find by experiment the mixture (mol ratio is 15:1~20:1) of celecoxib and methotrexate, can form amorphous complex under certain conditions, its texture is uniform, stability is good, solubility has greatly improved, solves methotrexate and celecoxib poor solubility, is difficult to disperse the problem, is conducive to the development of preparation.The application of the complex, not only improves the uniformity and drug loading of preparation, also improves preparation stability simultaneously, compared to comparative example patch, complex patch is placed under room temperature condition for March without property change and release behavior change.In addition, in subsequent transdermal experiments, find that the preparation transdermal effect prepared using amorphous complex is far beyond expectation, and this effect is inferred to be from the specific composition and proportioning of complex.

[0025] In order to solve the problem that methotrexate and celecoxib cannot be mixed evenly during the development of the complex preparation method, the solvent volatilization method is used to try to add different solvents such as tetrahydrofuran (THF), dimethyl sulfoxide (DMSO), disodium hydrogen phosphate aqueous solution and other solvents for dissolution according to the properties of the compound. Among them, tetrahydrofuran has poor solubility in the mixture, which may lead to the inability to fully promote the long-range disordered arrangement of the complex. Although the disodium hydrogen phosphate solution has good solubility, the inorganic salts introduced after volatilization may affect the structure of the complex and easily induce the occurrence of crystal transformation. It is finally found that DMSO has the best solubility in the mixture, and the resulting complex has good properties and no crystal transformation. In addition, further studies have found that simple DMSO dissolution will have a negative impact on the content uniformity of the obtained product application preparation, and it also shows that the formation and dispersion of amorphous complexes do not completely depend on the solubility of the selected solvent. After multi-angle analysis and investigation, it is finally found that oxygen in the air has a greater influence on the formation process of the complex, and the complex product obtained under nitrogen conditions is subsequently applied under air conditions, and the product content uniformity can be guaranteed, and the principle needs further study. The speculation about the enhanced transdermal effect is that DMSO can be used as a penetration enhancer, but due to technical limitations, it is unknown whether DMSO participates in the complex process as a ligand to increase the permeability of the complex, or whether it has a direct penetration enhancing effect due to incomplete volatilization and trace residues. In response to the possible skin allergy irritation caused by this speculation, general observations and pathological observations of animal experiments were subsequently conducted, and no abnormalities were found. BRIEF DESCRIPTION OF THE DRAWINGS

[0026] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are only embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on the provided drawings without paying creative work.

[0027] Figure 1 The accompanying drawings are DSC graphs of celecoxib, methotrexate, Example 1, and Comparative Examples 1-3;

[0028] Figure 2 The accompanying drawings are XRPD results of celecoxib, methotrexate, Example 1, and Comparative Example 1;

[0029] Figure 3 The attached figure shows the release data of celecoxib in experimental groups 1 to 6;

[0030] Figure 4 The attached figure shows the methotrexate release data of experimental groups 1 to 6;

[0031] Figure 5The attached figure shows the release data of celecoxib at 0 o'clock and 3 months in experimental group 1, experimental group 8 and experimental group 12;

[0032] Figure 6 The attached figure shows the release data of methotrexate at 0 o'clock and 3 months in experimental group 1, experimental group 8 and experimental group 12;

[0033] Figure 7 The attached figure shows the transdermal data of celecoxib in experimental group 1, experimental group 8 and experimental group 12;

[0034] Figure 8 The attached drawings show the transdermal data of methotrexate in experimental groups 1, 8 and 12. DETAILED DESCRIPTION

[0035] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0036] Example 1

[0037] An amorphous complex of methotrexate and celecoxib, the preparation process of which is as follows:

[0038] Weigh 50 parts of methotrexate and celecoxib in a molar ratio of 1:15, add 5 parts of DMSO to aid dissolution, place in a three-necked flask and pass nitrogen, heat to 170°C in an oil bath, stir at 300rpm for 2 hours, then reduce the temperature to 130°C, stir at 100rpm for 30 minutes, stop stirring and leave at this temperature for 24 hours, and cool to room temperature to obtain the product.

[0039] Example 2

[0040] An amorphous complex of methotrexate and celecoxib, the preparation process of which is as follows:

[0041] Weigh 50 parts of methotrexate and celecoxib in a molar ratio of 1:20, add 5 parts of DMSO to aid dissolution, place in a three-necked flask and pass nitrogen, heat to 170°C in an oil bath, stir at 300rpm for 2 hours, then reduce the temperature to 130°C, stir at 100rpm for 30 minutes, stop stirring and leave at this temperature for 24 hours, and cool to room temperature to obtain the product.

[0042] Example 3

[0043] An amorphous complex of methotrexate and celecoxib, the preparation process of which is as follows:

[0044] Weigh 50 parts of methotrexate and celecoxib in a molar ratio of 1:17, add 5 parts of DMSO to aid dissolution, place in a three-necked flask and pass nitrogen, heat to 160°C in an oil bath, stir at 400rpm for 1 hour, then reduce the temperature to 120°C, stir at 100rpm for 30 minutes, stop stirring and leave at this temperature for 24 hours, and cool to room temperature to obtain the product.

[0045] Example 4

[0046] An amorphous complex of methotrexate and celecoxib, the preparation process of which is as follows:

[0047] Weigh 50 parts of methotrexate and celecoxib in a molar ratio of 1:18, add 5 parts of DMSO to aid dissolution, place in a three-necked flask and pass nitrogen, heat to 180°C in an oil bath, stir at 200rpm for 1 hour, then reduce the temperature to 140°C, stir at 100rpm for 30 minutes, stop stirring and leave at this temperature for 24 hours, and cool to room temperature to obtain the product.

[0048] Example 5

[0049] An amorphous complex of methotrexate and celecoxib, the preparation process of which is as follows:

[0050] Weigh 50 parts of methotrexate and celecoxib in a molar ratio of 1:15, add 5 parts of DMSO to aid dissolution, place in a three-necked flask and pass nitrogen, heat to 160°C in an oil bath, stir at 200rpm for 2 hours, then reduce the temperature to 130°C, stir at 100rpm for 30 minutes, stop stirring and leave at this temperature for 24 hours, and cool to room temperature to obtain the product.

[0051] Example 6

[0052] An amorphous complex of methotrexate and celecoxib, the preparation process of which is as follows:

[0053] Weigh 50 parts of methotrexate and celecoxib in a molar ratio of 1:15, add 5 parts of DMSO to aid dissolution, place in a three-necked flask and pass nitrogen, heat to 180°C in an oil bath, stir at 400rpm for 1 hour, then reduce the temperature to 130°C, stir at 100rpm for 30 minutes, stop stirring and leave at this temperature for 24 hours, and cool to room temperature to obtain the product.

[0054] Examples 1 to 6 explore the range of temperature, rotation speed, and stirring time during the preparation of the composite.

[0055] Comparative Example 1 (physical mixing)

[0056] Weigh 50 parts of methotrexate and celecoxib in a molar ratio of 1:15, put them in a three-necked flask, and stir at 300 rpm for 2 hours to obtain the product.

[0057] Comparative Example 2 (Heating Co-melting)

[0058] Weigh 50 parts of methotrexate and celecoxib in a molar ratio of 1:15, place in a three-necked flask, heat to 170° C. in an oil bath, stir at 300 rpm for 2 hours, and cool to room temperature to obtain the product.

[0059] Comparative Example 3 (Nitrogen Protection)

[0060] Weigh 50 parts of methotrexate and celecoxib in a molar ratio of 1:15, place in a three-necked flask and pass nitrogen, heat to 170° C. in an oil bath, stir at 300 rpm for 2 hours, and cool to room temperature to obtain the product.

[0061] Comparative Examples 1 to 3 are used to compare the characterization data of Example 1 to demonstrate the formation of an amorphous composite.

[0062] Comparative Example 4 (no heating, no nitrogen protection)

[0063] Weigh 50 parts of methotrexate and celecoxib in a molar ratio of 1:15, add 5 parts of DMSO to assist dissolution, place in a three-necked flask, and stir at 300 rpm for 1 hour to obtain the product.

[0064] Comparative Example 5 (no heating)

[0065] Weigh 50 parts of methotrexate and celecoxib in a molar ratio of 1:15, add 5 parts of DMSO to assist dissolution, place in a three-necked flask and pass nitrogen, stir at 300 rpm for 1 hour, and obtain the product.

[0066] Comparative Example 6 (without nitrogen protection)

[0067] Weigh 50 parts of methotrexate and celecoxib in a molar ratio of 1:15, add 5 parts of DMSO to dissolve, place in a three-necked flask, heat to 170°C in an oil bath, stir at 300rpm for 1 hour, then reduce the temperature to 130°C, stir at 100rpm for 30 minutes, stop stirring and leave at this temperature for 24 hours, and cool to room temperature to obtain.

[0068] Comparative Examples 4 to 6 are used to compare the release data of the application preparation of Example 1, and further define the conditions for forming a specific complex of the present invention.

[0069] The range of excipients used in different experimental groups was explored, and the distribution ratio of each component is shown in Table 1;

[0070] Table 1

[0071]

[0072]

[0073] The comparative proportions corresponding to different experimental groups are shown in Table 2;

[0074] Table 2

[0075]

[0076] Differential Scanning Calorimetry (DSC) Experiment

[0077] Differential scanning calorimeter was used to test different samples of Example 1 and Comparative Examples 1-3. The results are shown in the attached Figure 1 .

[0078] The DSC results show that celecoxib has an endothermic peak at around 160°C; methotrexate has endothermic peaks at around 100 and 240°C; the positions of the endothermic peaks at 100 and 160°C of Comparative Examples 1-2 remain unchanged, and the endothermic peak at 240°C is advanced to around 200°C, indicating that physical mixing and heating eutectic have a certain influence on the physicochemical properties of the two drugs, but it is not obvious; all endothermic peaks of the complex disappear, and the overall enthalpy change range decreases, indicating that the two drugs form an amorphous complex and can remain stable to a certain extent.

[0079] X-ray powder diffraction (XRPD) experiments

[0080] The X-ray powder diffraction method was used to test Example 1, Comparative Example 1, celecoxib and methotrexate. The results are shown in the attached Figure 2 .

[0081] XRD results showed that celecoxib and methotrexate did not undergo microstructural transformation when physically mixed, but could form an amorphous composite after specific treatment.

[0082] Paste content uniformity test

[0083] According to the content uniformity determination method "Chinese Pharmacopoeia 2020 Edition Part IV General Principles 0941", different preparations were cut into 2 cm 2 The relative content of the test samples was detected by HPLC.

[0084] Criteria:

[0085] If A+2.2S≤L, the content uniformity of the test sample meets the requirements;

[0086] If A+S>L, it does not meet the requirements;

[0087] If A+2.2S>L, and A+S≤L, 20 more samples of the test sample should be taken for retest.

[0088] Take the 30 initial and retests and calculate them and then judge according to the following formula:

[0089] When A≤0.25L, if A 2 +S2 ≤0.25L 2 , then the content uniformity of the test sample meets the requirements, otherwise it does not meet the requirements;

[0090] When A>0.25L, if A+l.7S≤L, the content uniformity of the test sample meets the requirements, otherwise it does not meet the regulations.

[0091] Where A is the absolute value of the difference between the labeled value and the mean, S is the standard deviation, and L = 25.0.

[0092] Content uniformity test data (celecoxib), see Table 3;

[0093] Table 3

[0094]

[0095] Experimental groups 1 to 2 met the standards, while experimental groups 7, 9, 10, and 11 failed to meet the standards. Among them, the average content of experimental group 7 (physical mixture) was significantly lower, which obviously could not meet the preparation requirements.

[0096] Release test

[0097] According to the release rate determination method "Chinese Pharmacopoeia 2020 Edition Part IV General Rules 0931 Method 4", the dissolution release behavior of different preparations was investigated in appropriate media using a dissolution apparatus. Samples were taken at 0.5h, 1h, 2h, 3h, 6h, 12h and 24h, and HPLC analysis was performed to calculate the cumulative release rate.

[0098] The release behaviors of celecoxib and methotrexate in experimental groups 1 to 6 were similar, indicating that the preparation method of the complex within the scope of the present invention is stable. Figure 3 , Attachment Figure 4 .

[0099] The release behaviors of celecoxib and methotrexate in the initial sample and the sample after long-term storage for 3 months in experimental group 1 were basically unchanged and remained stable; compared with experimental group 1, the release of celecoxib and methotrexate in experimental groups 8 and 12 at 0 was lower, and the release was further reduced after long-term storage for 3 months, indicating that simple physical mixing cannot maintain a stable release behavior of the drug composition in the preparation, see attached Figure 5 , Attachment Figure 6 .

[0100] In vitro skin permeation test

[0101] The in vitro permeation test was conducted according to the U.S. FDA in vitro permeation technical guide "in vitro permeation tests studies for topical drug products submitted in ANDAs", and the modified Franz diffusion cell method was used for evaluation. The test skin was the back skin of Bama Xiang pigs. Samples were taken at 0.5h, 1h, 2h, 3h, 6h, 12h and 24h, and HPLC analysis was performed to calculate the cumulative permeation amount.

[0102] The data show that the drug permeation of the complex prepared under the specific conditions of the present invention is far superior to that of a simple physical mixture or drug solution. Figure 7 , Attachment Figure 8 .

[0103] Since comparative examples 2 and 3 were carbonized and discolored after heating, they were not prepared into preparations. Comparative examples 1, 4, 5, and 6 with relatively good properties were used to try to prepare preparations, namely experimental groups 7, 9, 10, and 11, and the content uniformity was investigated. Since the content uniformity was unqualified, even if the release and transdermal investigation results were carried out, they were not accurate (the error was large and the data was unreliable). The subsequent investigation continued to investigate whether reducing the drug loading of comparative examples 1 and 6 (mainly investigating comparative example 1, comparative example 6 had relatively good content uniformity in each group) could improve the content uniformity to support subsequent release and transdermal tests, namely experimental groups 8 and 12 (50 parts were changed to 30 parts). In fact, the content uniformity of experimental groups 8 and 12 was also investigated. The results showed that the content uniformity of experimental groups 8 and 12 was improved to a certain extent (A and S became smaller) but still did not meet the standards. Therefore, the release and transdermal experiments conducted later can only be said to have reference value to a certain extent, and cannot be used as a strict comparison standard. The comparative example reduces the drug loading and may also reduce the transdermal amount at the same time, but it also reflects the advantages of the drug loading of the present invention from the side.

[0104] The various embodiments in this specification are described in a progressive manner, and each embodiment focuses on the differences from other embodiments. The same or similar parts between the various embodiments can be referenced to each other.

[0105] The above description of the disclosed embodiments enables one skilled in the art to implement or use the present invention. Various modifications to these embodiments will be apparent to one skilled in the art, and the general principles defined herein may be implemented in other embodiments without departing from the spirit or scope of the present invention. Therefore, the present invention will not be limited to the embodiments shown herein, but rather to the widest scope consistent with the principles and novel features disclosed herein.

Claims

1. Use of an amorphous complex formed by methotrexate and celecoxib in the preparation of a patch for treating rheumatoid arthritis, wherein the patch is a gel patch; The preparation process of the amorphous composite is as follows: methotrexate and celecoxib are mixed, dimethyl sulfoxide is added thereto to dissolve, and the mixture is reacted in a nitrogen atmosphere to prepare the amorphous composite, wherein the molar ratio of methotrexate to celecoxib is 1:15 to 1:20, and the amount of dimethyl sulfoxide added is 1 / 10 of the mass of the mixture of methotrexate and celecoxib; The reaction in a nitrogen atmosphere is as follows: heat in an oil bath to 160-180°C, stir at 200-400 rpm for 1-2 hours, then lower the temperature to 120-140°C, stir at 100 rpm for 30 minutes, stop stirring and place at this temperature for 24 hours, and cool to room temperature to obtain a shiny yellow to orange solid.

2. The use according to claim 1, It is characterized in that The gel patch comprises the following raw materials in parts by weight: 50 parts of amorphous composite, 5-10 parts of emulsifier, 5-10 parts of auxiliary emulsifier, 50-80 parts of skeleton material, 60-80 parts of viscosity enhancer, 10-15 parts of stabilizer, 2-5 parts of whitening agent, 1-3 parts of cross-linking agent, 10-15 parts of regulator, 200-300 parts of moisturizer and 350-450 parts of water.

3. The use according to claim 2, It is characterized in that The emulsifier is Tween 60 or Tween 80, the co-emulsifier is Span 80 or Span 83, the skeleton material is polyacrylic acid and sodium polyacrylate, the viscosity enhancer is carboxymethyl cellulose or sodium carboxymethyl cellulose, the stabilizer is polyvinyl alcohol, the whitening agent is titanium dioxide, the cross-linking agent is aluminum glycolate or aluminum hydroxide, the regulator is tartaric acid, sodium tartrate or disodium edetate, and the moisturizer is glycerol or propylene glycol.

4. The use according to claim 3, It is characterized in that The gel patch process includes: 1) Weigh the compound, emulsifier and co-emulsifier in the formula and disperse them into the moisturizer, stirring at 100 rpm to 300 rpm until the mixture is evenly dispersed; 2) Weigh the formulated amount of stabilizer and regulator, disperse them in water, and stir at 50-150 rpm until completely dissolved; 3) weighing the skeleton material, tackifier and whitening agent in the formula amount and putting them into the reaction kettle, stirring at 400-600 rpm for 10-30 min, adding the moisturizer while stirring until a uniform paste is formed, then adding the dispersion obtained in step 1), stirring at 100-300 rpm for 10-30 min, and finally adding the crosslinking agent and the solution obtained in step 2), stirring at 100-300 rpm for 10-30 min to form a uniform paste; 4) Spread the paste evenly between the backing layer and the protective layer, cut into suitable size and shape as required, put into suitable packaging, and leave for 14 days to obtain the gel patch.